Biogen (XTER:IDP) Cyclically Adjusted PS Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:IDP Biogen Inc XTER:IDP
54 GF Score
Price €177.42
GF Value €169.53
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen  (XTER:IDP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biogen Cyclically Adjusted PS Ratio Related Terms


Biogen Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted PS Ratio Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.91 4.00 3.47 1.96 2.19

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.73 2.19 2.24 2.61

XTER:IDP vs OGN, AMRN, SCLX: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.


XTER:IDP
54GF Score
Biogen Inc XTER:IDP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Biogen's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.971/333.9520*333.9520
=15.971

Current CPI (Jun. 2026) = 333.9520.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 12.004 241.428 16.604
201612 12.547 241.432 17.355
201703 12.172 243.801 16.673
201706 12.911 244.955 17.602
201709 12.192 246.819 16.496
201712 13.175 246.524 17.847
201803 11.995 249.554 16.052
201806 13.860 251.989 18.368
201809 14.597 252.439 19.310
201812 15.483 251.233 20.581
201903 15.678 254.202 20.597
201906 16.811 256.143 21.918
201909 17.746 256.759 23.081
201912 18.552 256.974 24.109
202003 18.478 258.115 23.907
202006 20.319 257.797 26.321
202009 18.234 260.280 23.395
202012 15.216 260.474 19.508
202103 14.859 264.877 18.734
202106 15.345 271.696 18.861
202109 15.895 274.310 19.351
202112 16.403 278.802 19.648
202203 15.575 287.504 18.091
202206 16.753 296.311 18.881
202209 17.497 296.808 19.687
202212 16.517 296.797 18.585
202303 15.843 301.836 17.529
202306 15.580 305.109 17.053
202309 16.374 307.789 17.766
202312 14.998 306.746 16.328
202403 14.443 312.332 15.443
202406 15.695 314.175 16.683
202409 15.207 315.301 16.107
202412 16.067 315.605 17.001
202503 15.339 319.799 16.018
202506 15.635 322.561 16.187
202509 14.681 324.800 15.095
202512 13.153 324.054 13.555
202603 14.443 330.213 14.607
202606 15.971 333.952 15.971

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Biogen (XTER:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €177.42 is trading 4.7% above its estimated GF Value™ of €169.53. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for XTER:IDP:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €169.53 vs. price of €177.42 (4.7% above fair value)
  • GF Score™: 54/100 with 9 warning signs

No single metric tells the full story. See the XTER:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
54GF Score

Get the complete analysis for XTER:IDP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€177.42
Price
€169.53
GF Value